Treatment of CT26-tumor bearing mice with anti-PD-1 treatment (4 x 200 μg) and FMT (4 x (5x109 CFU)) from healthy human donors led to improved survival and reduced tumor growth (Huang et al., 2022). Here, DDX53 is linked to neoplasm.